Nelarabine in the treatment of refractory T-Cell malignancies

Clinical Medicine Insights: Oncology

Volumn 4, Issue , 2010, Pages 133-141

  Roecker, Andrew M ^a   Stockert, Amy ^a   Kisor, David F ^a  

^a OHIO NORTHERN UNIVERSITY   (United States)

Author keywords

Arranon; Atriance; Leukemia; Lymphoma; Nelarabine; T cell

Indexed keywords

ARABINOSIDE GUANOSINE TRIPHOSPHATE; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; GUANINE ARABINOSIDE; GUANOSINE TRIPHOSPHATE; NELARABINE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; AMNESIA; ANEMIA; AREA UNDER THE CURVE; ATAXIA; BALANCE IMPAIRMENT; BLOOD DYSCRASIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSFORMATION; FATIGUE; HUMAN; LYMPHOBLASTOMA; MALAISE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PARAPLEGIA; PARESTHESIA; PERIPHERAL NEUROPATHY; REVIEW; SENSORIMOTOR NEUROPATHY; SENSORY DYSFUNCTION; SOMNOLENCE; THROMBOCYTOPENIA; TREMOR;

EID: 79751508945     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S4364     Document Type: Review

References (28)

1. American Cancer Society. Cancer facts and figures 2010. Atlanta (GA): American Cancer Society;2010.
2. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukemia. Lancet. 2008;371:1030-43.
3. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN practice guidelines in oncology - non-hodgkin's lymphomas. National Comprehensive Cancer Network, Inc:2010 Oct. Available at: http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf. Accessed 2010 Oct 27.
4. Getting the facts: T-cell lymphomas. Lymphoma Research Foundation. 2008; Mar:1-4.
5. National PBM monograph: nelarabine (Arranon®). 2007 Jan. Available at: http://www.pbm.va.gov/clinical%20guidance/drug%20monographs/nelarabine.pdf. Accessed 2010 Oct 27.
6. Rodriguez CO, Gandhi V. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res. 1999;59:4937-43.
7. Rodriguez CO, Mitchell BS, Ayres M, Eriksson S, Gandhi V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. 2002;62:3000-5.
8. Gandhi V, Mineishi S, Huang P, et al. Cytotoxicity, metabolism, and mechanism of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res. 1995;55:1517-24.
9. Prus KL, Averett DR, Zimmerman TP. Transport and metabolism of 9-9-Darabinofuranosylguanine in a human T-lymphoblastoid cell line: nitrobenzylthioinosine- sensitive and -insensitive influx. Cancer Res. 1990;50:1817-21.
10. Scharenberg JG, Spaapen LJ, Rijkers GT, et al. Mechanism of deoxyguanosine toxicity for human T and B lymphocytes. Adv Exp Med Bio. 1986;195B:191-9.
11. Rodriguez CO, Stellrecht CM, Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood. 2003;102:1842-8.
12. Gandhi V, Plunkett W, Rodriguez CO, et al. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular Pharmacokinetics and clinical response. J Clin Oncol. 1998;16:3607-15.
13. Kisor DF, Plunkett W, Kurtzberg J, et al. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol. 2000;18:995-1003.
14. Kurtzberg J, Ernst TJ, Keating MJ, et al. A phase I study of 2-amino-9-1-Darabinofuranosyl- 6-methoxy-9Hpurine (506U78 [nelarabine]) administered on a consecutive five day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005;23:3396-403.
15. European Medicines Agency. Atriance (nelarabine): summary 2007 Jun 15;109(12):5136-42 of product information [online]. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/atriance/. Accessed 2010 Oct 27.
16. Gandhi V, Plunkett W, Weller S, et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics and pharmacodynamics in leukemia cells. J Clin Oncol. 2001;19:2142-52.
17. Rodriguez COR, Legha JK, Estey E, Keating MJ, Gandhi V. Pharmacological and biochemical strategies to increase accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells. Clin Cancer Res. 1997;3:2107-13.
18. Gandhi V, Plunkett W. Interaction of arabinosyl nucleotides in K562 human leukemia cells. Biochem Pharmacol. 1989;38:3551-8.
19. Gandhi V, Plunkett W. Modulation arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988;48:329-34.
20. DeAngelo DJ, Yu D, Dodge RK, et al. A phase II study of 2-amino-9-2-D-arabinosyl-6-methoxy-9H-purine (506U78) in patients with relapse of refractory T-lineage acute lymphoblastic leukemias (ALL) of lymphoblastic lymphoma (LBL) (abstract): CALGB Study 19801. Blood. 2002;100:742.
21. DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007;109:5136-42.
22. Goy A, Bleyer A, Hagemeister F, et al. Phase II study of compound GW506U78 (araG) for patients with indolent B-cell or peripheral T-cell lymphoma previously treated with chemotherapy. 45th Annual Meeting American Society of Hematology. San Diego, USA;2003. (Abstract 2359).
23. Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005;23:3376-82.
24. Czuczman MS, Porcu P, Johnson J, et al. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma. 2007;48(1):97-103.
25. Gandhi V, Tam C, O'Brien S, et al. Phase I trial of nelarabine in indolent leukemias. J Clin Oncol. 2008;26(7):1098-1105.
26. Commander LA, Seif AE, Insogna IG, Rheingold SR. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory pediatric T-cell lymphoblastic leukemia and lymphoma. Brit J Hematol. 2010;150:345-51.
27. GlaxoSmithKline: Arranon® (nelarabine) injection for intravenous use (product information). Research Triangle Park, NC, USA;2005.
28. Papayannidis C, Iacobucci I, Abbenante MC, et al. Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. Am J Hematol. 2010;85:608.